CeraPedics Receives $19,000,000 Series C Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7b7dbff2-2fe1-4b7d-8d45-306748f8515b&Preview=1 - Date
12/12/2012 - Company Name
CeraPedics - Mailing Address
11025 Dover Street Westminster, CO 80021 - Company Description
CeraPedics, Inc. is developing and commercializing products for the orthopedic bone substitutes market. The Company’s products utilize a proprietary small peptide called P-15. CeraPedics’ products should provide a safe, efficacious, and economical alternative to autograft and recombinant bone growth factor products for most procedures requiring a bone graft including spine fusion, trauma, and joint reconstruction. - Website
http://www.cerapedics.com - Transaction Type
Venture Equity - Transaction Amount
$19,000,000 - Transaction Round
Series C - Proceeds Purposes
Proceeds will be used to support the company’s ongoing activities with its current Investigational Device Exemption (IDE) clinical trial in the United States studying its i-FACTOR(TM) peptide enhanced bone graft for cervical spine applications and prepare for commercialization upon FDA approval. - M&A Terms
- Venture Investor
MedImmune Ventures - Venture Investor
OrbiMed Advisors - Venture Investor
NGN Capital - Venture Investor
CVF LLC
